Targeting the Mutation, Not the Disease is Bringing Treatment to the Ultra-Rare Community
Source: pixabay.com

Targeting the Mutation, Not the Disease is Bringing Treatment to the Ultra-Rare Community

The U.S. FDA just announced that it has accepted Genentech’s supplemental New Drug Application (sNDA) and has granted Priority Review for Zelboraf (vemurafenib) in patients with Erdheim-Chester disease from the…

Continue Reading Targeting the Mutation, Not the Disease is Bringing Treatment to the Ultra-Rare Community
This WM Patient from Across the Pond Has Been Reconnected With His Donor
Source: pixabay.com

This WM Patient from Across the Pond Has Been Reconnected With His Donor

Waldenstrom macroglobulinemia (WM) is a devastating form of non-Hodgkins lymphoma. Specifically, this cancer starts in the B cells of the body (B lymphocytes). Waldenstrom's cancer cells are capable of making…

Continue Reading This WM Patient from Across the Pond Has Been Reconnected With His Donor
This FDA Approval for Haegarda Just Changed Lives
https://pixabay.com/en/morning-sunrise-woman-silhouette-2243465/

This FDA Approval for Haegarda Just Changed Lives

A new therapy option for hereditary angioedema (HAE) has recently received FDA approval! Marketed as Haegarda by biopharmaceutical company, CSL Behring, this subcutaneous C1 Esterase Inhibitor is now usable in…

Continue Reading This FDA Approval for Haegarda Just Changed Lives